More firms weigh IPOs as biotech fever reaches Europe

[riky]

More firms weigh IPOs as biotech fever reaches Europe

<p><a href="http://news.yahoo.com/more-firms-weigh-ipos-biotech-fever-reaches-europe-145508349--sector.html"><img src="http://l1.yimg.com/bt/api/res/1.2/ApMA_p84TxGV_1sIdB0_9g--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-03-13T145508Z_1_CBREA2C15G900_RTROPTP_2_CBUSINESS-US-BIOTECH-IPOS-EUROPE.JPG" width="130" height="86" alt="A general view shows Swiss biotech group Actelion Headquarters in Allschwil" align="left" title="A general view shows Swiss biotech group Actelion Headquarters in Allschwil" border="0" /></a>By Ben Hirschler and Caroline Copley LONDON/ZURICH (Reuters) - Biotech fever is spreading to Europe from the United States with a successful stock market debut for a cat allergy company in Britain seen as a bellwether that could help unlock listings in other countries including Switzerland and France. Top candidates for a share sale include Swiss firms AC Immune and Molecular Partners, which are both weighing up a possible initial public offering (IPO), according to people familiar with the companies. Geneva-based Novimmune named Andrew Oakley, the former chief financial officer of Europe's biggest biotech Actelion , as its new finance chief on Wednesday - also raising expectations that the firm is beefing up its management team in preparation to go public. Sentiment was given a major boost on Thursday when British allergy drug development firm Circassia raised around 581 million pounds ($965 million) in its London listing, a record-breaking sum for a European biotech.</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login